Replies to post #31442 on Biotech Values

[drbio45]

They met 2 of 3 primary endpoints in the last trial

if they don't meet 3 of 3 in the next one it won't get approved


I believe that is the case

[bladerunner1717]

re: ACUS

ACUS was one of Evan Sturza's top picks as he closed out his biotech newsletter. As late as 6/15/06, he had a $12 price target on the stock (no time frame specified, but he expected RAMP-2 to be successful and topline data to be available 4Q06.) I doubt if this helps much, but I thought I'd throw it in. Maybe PGS or others can chime in on the ability of these contrast agents to detect CAD.


Bladerunner